The dataset behind every page
The dataset holds 42 GLP-1 telehealth program records re-read on November 20, 2026: compounded tirzepatide and semaglutide month-to-month all-in prices, the lowest printed rate and its condition, membership, billing cycle, dose pricing, read status, source URL and the August 2026 capture kept as history. Download it, check any price against its source, and hold us to it.
Released · Last reviewed · how we verify
providers.json
Full records, with the November 20, 2026 read under nov20 and computed scores under computed.
providers.csv
One row per program with the November 20 figures and the August capture columns.
License and citation
CC BY 4.0. Reuse with attribution to TopGLP1Providers.com and carry the read date with any figure. Suggested citation: “TopGLP1Providers GLP-1 Provider Price Index, re-read 2026-11-20, https://topglp1providers.com/data/.”
Field notes
Prices are USD per billing cycle; cycle_days 28 marks four-week billing. All-in means medication plus any required recurring fee, with a yearly membership divided by 12. null means no comparable price was printed or the page could not be read, never zero. status is verified, changed, promotional, unreachable or not-read. The August 2026 columns are kept for history and are not current prices.
Frequently asked
How current are the prices on TopGLP1Providers?
Every price on TopGLP1Providers carries the date it was read on the program’s own page; the whole dataset was re-read on November 20, 2026, from 2026-11-21 00:33 to 00:57 UTC, and NexLife’s plan pages were checked again for this site on November 21 (UTC). Programs whose pages refused automated reads that day, such as TrimRx, MEDVi, bmiMD, Embody, Ro and Hims & Hers, show no current price rather than an older one. When a program changes its price, the record, the pages that cite it and the changelog are updated together.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)